Photo Gallery


S. Compound is a proprietary herbal formulation based on Sallaki (Boswellia Serrata), a non-steroidal, anti-arthritic, and 100% herbal formulation. It is totally free from chemicals, synthetics and heavy metals (even as excipients), and is wholly safe and non-toxic in nature. S. Compound is a new class of disease modifying formulation, with a novel mode of action. Developed after several years of research, the main constituent of this pure plant product is Salai Guggul (Boswellia Serrata). Historically, this product is mentioned in Sushruta Samhita Sutra Sthanam 4, an ancient Ayurvedic text.



COMPOSITION: S. Compound (Boswellia Serrata) processed in herbal extracts (Rasnadi & Suranjan) 300 mg.

CHEMICAL COMPOSITION: Boswellic acids are a complex mixture of Pentacyclic Triterpenic acids:

β-boswellic acids

Acetyl-β-boswellic acid

I I-Keto-β-boswellic acids

Acetyl-I I-Keto-β-boswellic acids.


Efficaciousness proved in Controlled Studies

Controlled Studies at the Government Ayurvedic College Hospital and Government Medical College (both in Jammu), were conducted, established its efficacy in the treatment of Rheumatoid Arthritis and Osteo Arthritis.


Meeting International Standards

S. Compound is manufactured by Rahul Pharma at its state-of-the-art, GMP Certified facilities at Jammu.   

All raw materials, including gelatin capsules and plastic containers used in the processing to the finished product, are sourced from reputed, GMP certified companies or directly from the forest area under the supervision of experts.

Gum is purified and then processed in the ingredients of Raasnadi (a classical Ayurvedic composition based on medicinal plants mentioned in Ayurvedic Texts/Suranjan).

Manufacturing / Processing Formulations under advisory consultancy from Regional Research Laboratory, Jammu, a unit of Counil of Scientific & Industrial Research (CSIR), Government of India.




A conventional, non-steroidal, anti-inflammatory agent, the action of S. Compound is mediated through the vascular phenomenon. It improves the blood supply to the joints and restores integrity of vessels obliterated by the spasm of internal damage. It exerts its action through inhibition of lipoxygenase enzyme, on the formation of Leukotreine LTB4, a novel mode of action till now. Unlike other non-steroidal anti-inflammatory drugs, S.Compound has beneficial and therapeutic effects. It has been found to be free from pre-clinical acute and chronic toxicity. Clinical studies at Government Medical College and Regional Research Laboratory, Jammu have established it to be a safe anti-arthritic and anti-asthmatic drug.




Chronic Toxicity in rabits for three months: Salai Guggul in 2% gum acacia in two doses and one control of 2% gum acacia were administered orally in three groups of rabits. Hematological and biochemical estimation revealed no deviation from normal parameters. Macroscopic and microscopic examination of vital organs revealed no change in weight, size, coloration and histo-pathology. Chronic toxicity in monkeys also showed no change in hematological and biochemical parameters.

Analysis of S. Compound (Boswellia Serrata)

(Processed in herbal extracts 300 mg)

General Information

Type of formulation

Dry powder in black / maroon capsule "0" size

Plant part used

Gum exudates, leaves, branches, and roots


Wild crafted

Shelf Life

36 months unopened


Cool, dry place protected from moisture and heat

Active ingredient

Boswellic acid

Method of analysis


Analytical Specifications


Highly hygroscopic

Organoleptic characters

Bitter, astringent and sour in taste, with characteristic odour

Moisture Content

Not more than 20.5% W/W

Boswellic Acid Content

Not less than 0.5%


Not more than 10 PPM


Not more than 2 PPM

Heavy metals

Not more than 20 PPM


Boswellic acids content on dry basis by Titrimetry

Microbiological Profile

Total bacterial count

Not more than 10000 CFU/gm

Yeasts and moulds

Not more than 100 CFU/gm





Salmonella typhi


Pseudomonas aeruginose


To detect it, BP 2001, WHO / Pharma / 92.559 was employed.



Government of India

In 1985, the Advisor Ayurveda, Ministry of Health & Family Welfare, Government of India, sought information about S. Compound, and a test report from Central Drug Research Institute (CDRI), Lucknow, was obtained. After clinical studies, CDRI established is better activity as compared to Phenylbutazone, a drug withdrawn from a number of countries due to its toxic effects.


Post Graduate Department of Medicine, Government Medical College, Jammu

Further work on Osteo Arthritis taken up by the Post Graduate Department of Medicine, Government Medical College, Jammu, also confirmed S. Compound's efficacy in its treatment. The research work was published in Indian Practitioner.


Directorate of Indian System of Medicine, Jammu & Kashmir

After the creation of Directorate of Indian System of Medicines in J&K state in 1988, it took up trials of S. Compound and certified its efficacy. The formulation was tested by Ayurvedic experts on thousands of patients in more than 400 dispensaries.


Department of Pharmaceutical Sciences, Tubingen University, Germany

The Department of Pharmaceutical Sciences, Tubingen University, Germany, has established S. Compound as a Leukotreine Inhibitor, and that it has efficacy in all inflammatory conditions.


Published Research Work in International Journals

Research work on S. Compound has been published in international medical journals such as Planta Medica and the European Journal of Medical Research.


Efficaciousness proved in Controlled Studies

Controlled Studies at the Government Ayurvedic College Hospital and Government Medical College (both in Jammu), were conducted, established its efficacy in the treatment of Rheumatoid arthritis and Osteo Arthritis.


National and International Accolades for S. Compound


Hope for Arthritis patients

New Delhi, June 21 (UNI)

It was observed during trials conducted in patients suffering from Chronic Rheumatoid Arthritis that the formulation afforded between 70-80% relief with regard to swelling in joints and tenderness, morning stiffness, walking time and patients own impressions of overall disease activity. According to Eastern Pharmacist, a leading Pharmaceutical journal, it appears that the formulation acts on the basic pathological process responsible for the genesis of Rheumatoid Arthritis.

Courtesy: Hindustan Times, Times of India, National Herald, The Statesman, The Tribune, June 22, 1982


S. Compound: A traditional drug for Osteo Arthritis

The Indian Practitioner: January 1993

S. Compound was tried on 30 patients of chronic Osteo Arthritis of primary aetiology. While 60% of the patients started showing improvement in symptoms by the second week, and by twelve weeks had full relief, 33.3% of the patients had o take the formulation for twenty four weeks for full relief. In the control group treated with Ibuprofen, only 30% showed improvement. Very few side effects were noted in the patients treated with S. Compound as compared to patients treated with Ibuprofen.

The study was carried out by Deptt. of Post Graduate Medicine, Government Medical College, Jammu.


S. Compound has benefited thousands of patients of crippling disorders

Dr Hardyal Singh, M.D., MNAMS, Director-Principal, Guru Ram Dass Institute of Medical Sciences & Research, Amritsar.


Health Minister's Statement in Indian Parliament

November, 1983

"Rahul Pharma, Jammu, has developed an Ayurvedic formulation named S. Compound. The main ingredient of the drug is Salai Guggul. This is claimed to be very effective for the treatment of Rheumatoid Arthritis."


Central Drug Research Institute, Lucknow

December 1984

"S. Compound has better activity than Phenylbutazone."


Studies with S. Compound in the treatment of Rheumatoid arthritis

Dr. Shayma Wanchoo, Assistant Director, Health Services, J&K Government and Dr. Gurmeet Singh, Medical Officer, Government Ayurvedic Dispensary, Jammu

The study was conducted on twenty patients ailing from Rheumatoid Arthritis and showing major symptoms like pain, swelling, stiffness, effusion of the joints and restriction of movement. They had marked morning stiffness.

Patients treated with S. Compound indicated excellent recovery during the course of treatment. Though progress varied in different patients, it was noticed that there was 75-85% relief with regard to morning stiffness, pain and swelling of the joints, walking time and the patients own impressions of overall disease activity.

It was observed that the noteworthy effect of S. Compound was due to its anti inflammatory, analgesic, anti arthritic action and also due to the prevention of degenerative changes. The most significant factor is that none of the patients was exposed to after effects during the treatment conducted with S. Compound.

Souvenir, All India Ayurvedic Meet, November 1983.

A ray of hope for Arthritis

Daily News, Colombo, Sri Lanka

There is heartening news for all those suffering from Rheumatic and other skeletal disorders. Thanks to Ayurvedic S. Compound, a herbal medicine developed by Dr. Virender Mahajan, illustrious son of late Dr. Som Nath Gupta Vaidya Vachaspati, an eminent Ayurvedic Physician hailing from Mirpur.

According to Dr. Mahajan, Director, Maharishi Charak Ayurvedic Centre for Rheumatic Diseases, S. Compound provides quick relief from pain, inflammation and tenderness without causing any side effects as in the case of Phenylbutazone, Ibuprofen and other synthetic medicines.

Rheumatic specialist declared Man of the Year

The Kashmir Times, Jammu, January 20, 2003

Kashmir Times News Service, January 19

American Biographical Institute Inc., North Carolina, USA, publishers of Biographical Reference works since 1967, has declared Dr. Virender Mahajan, Medical Director, Maharishi Charak Ayurvedic Centre for Rheumatic Diseases, Jammu, as the Man of the Year 2003.

A communication sent by its President J.M. Evans stated," I am delighted to announce your nomination for the prestigious title 'Man of the year 2003'. The Institute's International Board of Research decided on your nomination due to your overall accomplishments and contribution to the society."






Indian Journal of Pharmacology 12:1:P59:1980

Eastern Pharmacist XXV:P293:1982

British Pharmaco Congress UK April: 1981 C 49

All Indian Meet Souvenir Nov:1983

Sushruta Samhita S.S 38

The Indian Practitioner:XLVI : I:P 69:1993



Dravayagunavignyana, Continental Prakashan, Pune(1982)

Effects of Boswellia serrata gum resin in Patients with bronchial asthma: result of a double blind,placebo-controlled, 6-week clinical study.

Eur J Med Res.1998 Nov 17;3(11):5 1 1-4

Effects of gum resin of Boswellia  in Patients with chronic colitis.

Planta Med. 2001 Jul;67(5):391-5

Clastagenic effects of dietary supplement--Spirulina alga, and some medical plant products from Boswellia serrata, Withania somnifera on mice. Indian J Exp Biol.2001 oct:39(10):1068-70

High-performance thin layer chromatographic analysis of anti-inflammatory triterpenoids from Boswellia serrata Roxb.

PhytochemAnal.2001 Nov-Dec:12(6):374-6

Boswellic acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization.

Biochem Biophys Res Commun.002 Jan 11;290(1):185-90

A reversed phase high performance liquid chromatography method for the analysis of boswellia acid in Boswellia serrata.

Planta Med. 2001 Nov;67(8):778-80

Sitmulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid.

Mol Pharmacol 2001 Aug;60(2):67-73

Acetyl-11-Keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellic serrata resin, attenuates experimental ileitis.

Int J Colorectal Dis.2001 Apr: 16(2):88-95

Treatement of osteoarthritis with a herbomineral formulaion: a double-blind,placebo-controlled,cross-over study.

J Ethnopharmacol. 1991 May-June:33(1-2):91-

Mechanism of anti-carcinogenic activities of curcumineBoswellic acids.

J Ethnopharmacol. 1993 Mar: 38(2-3):113-9

Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-Boswellic acid. Biofactors.2000;13(1-4):225-30

Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata.

Planta Med. 1991,Jun;57(3):203-7

Therapy of active Crohn disease with Boswellia serrata extract H 15]

Z Gastroenterol.2001 Jan:39(1):11-7, German

The etiologies, Pathophysiology, and alternative/ complementary treatement of Asthma.

Altern Med Rev.2001 Feb;6(1):20:47

Salai Guggal-Boswellia serrata: from a herbal medicine to a non-redox inhibitor of leukotriene biosynthesis.

Eur J Med Res.1996 May 24:1(8):369-70

Effects of Boswellia acid extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis

Arzneimittelforschung.1998 Jun:48(6):668-74

Inhibitory activity of boswellic acid from Boswellia serrata against human leukemia HL-60 cells in culture.

Planta Med. 1998 May;64(4):328-31

Effects of Boswellia serrata gum resin in Patients with Ulcerative colitis. EJ Med Res 1997jan::37-43

Dr. Virendra Mahajan. All Rights Reserved

Powered by Ideogram Technology Solutions Private Limited